2型糖尿病患者的椎体骨折:不仅是骨骼并发症
该系统评价与荟萃分析纳入15项研究共852,705人,发现2型糖尿病与椎体骨折现患风险降低相关(OR 0.84),但椎体骨折发生风险增加(OR 1.35)。在19,820人的个体数据队列中,同时有2型糖尿病和椎体骨折者非椎体骨折和死亡风险显著高于仅有其一者。
要点
- 2型糖尿病患者椎体骨折发生风险增加35%,应系统评估椎体骨折。
- 2型糖尿病合并椎体骨折者非椎体骨折风险为无两者2.42倍。
- 2型糖尿病合并椎体骨折者死亡风险为无两者2.11倍。
核心结论
- 2型糖尿病患者椎体骨折发生风险增加,且合并椎体骨折提示非椎体骨折和死亡风险更高。
- 建议对2型糖尿病患者系统评估椎体骨折,发现后应启动骨质疏松治疗以预防未来骨折。
研究设计与样本
- 系统检索PubMed并纳入提供个体参与者数据的队列,采用随机效应荟萃分析。
- 共纳入15项研究,含852,705名男性和女性;个体数据队列样本量为19,820人。
主要发现
- 2型糖尿病与椎体骨折现患风险降低相关(OR 0.84,95%CI 0.74-0.95;I²=0.0%;Phet=0.54)。
- 2型糖尿病与椎体骨折发生风险增加相关(OR 1.35,95%CI 1.27-1.44;I²=0.6%;Phet=0.43)。
- 同时有2型糖尿病和椎体骨折者非椎体骨折风险高于无两者(HR 2.42,95%CI 1.86-3.15)、仅有椎体骨折者(HR 1.73,95%CI 1.32-2.27)或仅有2型糖尿病者(HR 1.94,95%CI 1.46-2.59)。
- 同时有2型糖尿病和椎体骨折者死亡风险高于无两者(HR 2.11,95%CI 1.72-2.59)或仅有椎体骨折者(HR 1.84,95%CI 1.49-2.28),与仅有2型糖尿病者相比为临界升高(HR 1.23,95%CI 0.99-1.52)。
临床怎么用
- 对2型糖尿病患者应系统评估椎体骨折的存在。
- 2型糖尿病患者发现椎体骨折应视为启动骨质疏松治疗的指征,以预防未来骨折。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to assess whether individuals with type 2 diabetes (T2D) have increased risk of vertebral fractures (VFs) and to estimate nonvertebral fracture and mortality risk among individuals with both prevalent T2D and VFs. RESEARCH DESIGN AND METHODS: A systematic PubMed search was performed to identify studies that investigated the relationship between T2D and VFs. Cohorts providing individual participant data (IPD) were also included. Estimates from published summary data and IPD cohorts were pooled in a random-effects meta-analysis. Multivariate Cox regression models were used to estimate nonvertebral fracture and mortality risk among individuals with T2D and VFs. RESULTS: Across 15 studies comprising 852,705 men and women, individuals with T2D had lower risk of prevalent (odds ratio [OR] 0.84 [95% CI 0.74-0.95]; I 2 = 0.0%; P het = 0.54) but increased risk of incident VFs (OR 1.35 [95% CI 1.27-1.44]; I 2 = 0.6%; P het = 0.43). In the IPD cohorts (N = 19,820), risk of nonvertebral fractures was higher in those with both T2D and VFs compared with those without T2D or VFs (hazard ratio [HR] 2.42 [95% CI 1.86-3.15]) or with VFs (HR 1.73 [95% CI 1.32-2.27]) or T2D (HR 1.94 [95% CI 1.46-2.59]) alone. Individuals with both T2D and VFs had increased mortality compared with individuals without T2D and VFs (HR 2.11 [95% CI 1.72-2.59]) or with VFs alone (HR 1.84 [95% CI 1.49-2.28]) and borderline increased compared with individuals with T2D alone (HR 1.23 [95% CI 0.99-1.52]). CONCLUSIONS: Based on our findings, individuals with T2D should be systematically assessed for presence of VFs, and, as in individuals without T2D, their presence constitutes an indication to start osteoporosis treatment for the prevention of future fractures.
引用
- Koromani F, Oei L, Shevroja E, et al. Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone. Diabetes Care. 2019. PMID: 31658976. doi:10.2337/dc19-0925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。